journal article·2026-04-13Open access

Improved MRSI in a Murine Glioma Model Using semiLASER: Refining the Metabolomics Data Obtained from Murine Models

Zoona Javed, Gary V. Martinez, Marta Mulero-Acevedo, Ana Paula Candiota, Carles Arus, Miquel E. Cabañas, Silvia Lope-Piedrafita

Applied Sciences· Volume 16· Issue 8

Abstract

Background: Magnetic resonance spectroscopic imaging (MRSI) offers valuable metabolic information for assessing brain tumor progression and therapeutic response, but its performance in rodent models is often hindered by the low signal-to-noise ratio (SNR) and spatially heterogeneous spectral quality, particularly in peripheral voxels. These issues reduce the number of usable spectra available for quantitative and classifier-based analyses. To address this, we implemented a multi-voxel MRSI-semiLASER sequence—widely recommended in clinical practice—on a 7T Bruker Biospec system running ParaVision 5.1 to improve spectral homogeneity in mouse brain tumor studies. Results: Compared with the vendor CSI-PRESS sequence, MRSI-semiLASER produced more uniform spectra across the grid and achieved up to a 1.2-fold SNR increase in murine glioma, enabling a 20% reduction in slice thickness without compromising spectral quality. Importantly, the sequence produced a substantial gain in the proportion of spectra amenable to analysis, particularly in outer grid voxels that frequently fail with CSI-PRESS. The implemented MRSI-semiLASER sequence and instructions are openly available to the community. Conclusions: MRSI-semiLASER improves spectral homogeneity, increases the proportion of usable spectra, and supports higher spatial detail. These technical improvements may enhance data yield per subject and may facilitate future applications such as more robust pattern recognition workflows and greater data efficiency in longitudinal studies, although such aspects were not evaluated here.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Glioma Diagnosis and Treatment · Advanced MRI Techniques and Applications · Metabolomics and Mass Spectrometry Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain

Servei de Ressonància Magnètica Nuclear, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain

Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 08193 Cerdanyola del Vallès, Spain

Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain

Departament de Bioquímica i Biologia Molecular, Unitat de Biofísica, Edifici M, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain

References (47)

Show source-provided references
1. Spectroscopic imaging: Basic principles10.1016/j.ejrad.2008.03.003 ↗
2. In vivo magnetic resonance spectroscopy: Basic methodology and clinical applications10.1007/s00249-009-0517-y ↗
3. Imaging based magnetic resonance spectroscopy (MRS) localization for quantitative neurochemical analysis and cerebral metabolism studies10.1016/j.ab.2017.01.007 ↗
4. Accelerated MR spectroscopic imaging—A review of current and emerging techniques10.1002/nbm.4314 ↗
5. Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment10.1016/j.rcl.2021.01.004 ↗
6. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis10.1002/nbm.3521 ↗
7. Imaging of cancer lipid metabolism in response to therapy10.1002/nbm.4070 ↗
8. Metabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models10.1002/nbm.4855 ↗
9. Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy (MRSinMRS): Experts’ consensus recommendations10.1002/nbm.4484 ↗
10. Horská, A., Berrington, A., Barker, P.B., and Tkáč, I. (2023). Magnetic Resonance Spectroscopy: Clinical Applications. Functional Neuroradiology: Principles and Clinical Applications, Springer. [2nd ed.].10.1007/978-3-031-10909-6_10 ↗
11. 1H-MRSI pattern perturbation in a mouse glioma: The effects of acute hyperglycemia and moderate hypothermia10.1002/nbm.1421 ↗
12. Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors10.1002/nbm.2832 ↗
13. Preclinical magnetic resonance imaging and spectroscopy in the fields of radiological technology, medical physics, and radiology10.1007/s12194-024-00785-y ↗
14. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy10.1111/j.1349-7006.2006.00208.x ↗
15. Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model10.1007/s13311-015-0407-1 ↗
16. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model10.1158/2326-6066.CIR-15-0151 ↗
17. Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: The devil is in the detail
18. Arias-Ramos, N., Ferrer-Font, L., Lope-Piedrafita, S., Mocioiu, V., Julià-Sapé, M., Pumarola, M., Arús, C., and Candiota, A.P. (2017). Metabolomics of therapy response in preclinical glioblastoma: A multi-slice MRSI-based volumetric analysis for noninvasive assessment of temozolomide treatment. Metabolites, 7.10.3390/metabo7020020 ↗
19. Ortega-Martorell, S., Olier, I., Hernandez, O., Restrepo-Galvis, P.D., Bellfield, R.A.A., and Candiota, A.P. (2023). Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks. Cancers, 15.10.3390/cancers15154002 ↗
20. Wu, S., Calero-Pérez, P., Arús, C., and Candiota, A.P. (2020). Anti-pd-1 immunotherapy in preclinical gl261 glioblastoma: Influence of therapeutic parameters and non-invasive response biomarker assessment with mrsi-based approaches. Int. J. Mol. Sci., 21.10.3390/ijms21228775 ↗
21. Calero-Pérez, P., Wu, S., Arús, C., and Candiota, A.P. (2021). Immune system-related changes in preclinical GL261 glioblastoma under TMZ treatment: Explaining MRSI-based nosological imaging findings with RT-PCR analyses. Cancers, 13.10.3390/cancers13112663 ↗
22. Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses10.1002/mrm.21302 ↗
23. Advanced single voxel 1H magnetic resonance spectroscopy techniques in humans: Experts’ consensus recommendations10.1002/nbm.4236 ↗
24. Simulated basis sets for semi-LASER: The impact of including shaped RF pulses and magnetic field gradients10.1007/s10334-020-00900-1 ↗
25. Realistic head-shaped phantom with brain-mimicking metabolites for 7 T spectroscopy and spectroscopic imaging10.1002/nbm.4421 ↗
26. Environmental stimuli shape microglial plasticity in glioma10.7554/eLife.33415 ↗
27. Anti-tumour immune response in GL261 glioblastoma generated by Temozolamide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images10.1002/nbm.4229 ↗
28. 2D-spatial/2D-spectral spectroscopic imaging of intracerebral gliomas in rat brain10.1002/(SICI)1522-2594(200002)43:2<211::AID-MRM7>3.0.CO;2-A ↗
29. Automatic, localized in Vivo adjustment of all first-and second-order shim coils10.1002/mrm.1910290613 ↗
30. A semi-LASER, single-voxel spectroscopic sequence with a minimal echo time of 20.1 ms in the human brain at 3 T10.1002/nbm.4324 ↗
31. Javed, Z. (2023). Implementation of High-Resolution MRSI Methods in a Pre-Clinical Scanner, and Optimization for Brain Longitudinal Studies of Therapy Response in Mice Glioma Models. [Doctoral Thesis, Universitat Autònoma de Barcelona]. Available online: https://hdl.handle.net/10803/690988.
32. Craven, A.R., Bell, T.K., Ersland, L., Harris, A.D., Hugdahl, K., and Oeltzschner, G. (2024). Linewidth-related bias in modelled concentration estimates from GABA-edited 1H-MRS. bioRxiv, bioRxiv:2024.02.27.582249.
33. SLIPMAT: A pipeline for extracting tissue-specific spectral profiles from 1H MR spectroscopic imaging data10.1016/j.neuroimage.2023.120235 ↗
34. Effects of noise and linewidth on in vivo analysis of glutamate at 3 Tesla10.1016/j.jmr.2020.106732 ↗
35. Advanced processing and simulation of MRS data using the FID appliance (FID-A)—An open source, MATLAB-based toolkit10.1002/mrm.26091 ↗
36. Carstensen, B. (2010). Comparing Clinical Measurement Methods: A Practical Guide. Comparing Clinical Measurement Methods: A Practical Guide, Wiley.10.1002/9780470683019 ↗
37. Metabolite concentrations of healthy mouse brain by Magnetic Resonance spectroscopy at 7 Tesla
38. Quality control of prostate 1H MRSI data10.1002/nbm.2835 ↗
39. Developments in proton MR spectroscopic imaging of prostate cancer10.1007/s10334-022-01011-9 ↗
40. Methodological consensus on clinical proton MRS of the brain: Review and recommendations10.1002/mrm.27742 ↗
41. Semi-LASER 1H MR spectroscopy at 7 Tesla in human brain: Metabolite quantification incorporating subject-specific macromolecule removal10.1002/mrm.25380 ↗
42. Across-vendor standardization of semi-LASER for single-voxel MRS at 3T10.1002/nbm.4218 ↗
43. Short symmetric and highly selective asymmetric first and second order gradient modulated offset independent adiabaticity (GOIA) pulses for applications in clinical MRS and MRSI10.1016/j.jmr.2022.107247 ↗
44. Diagnosis of transition zone prostate cancer by multiparametric MRI: Added value of MR spectroscopic imaging with sLASER volume selection10.1186/s12929-021-00750-6 ↗
45. Flexible proton 3D MR spectroscopic imaging of the prostate with low-power adiabatic pulses for volume selection and spiral readout10.1002/mrm.26181 ↗
46. 1H MMR spectroscopic imaging of the mouse brain at 9.4 T10.1002/jmri.20709 ↗
47. Quantitative in vivo 1H spectroscopic imaging of metabolites in the early postnatal mouse brain at 17.6 T10.1007/s10334-008-0142-2 ↗